What is SaMD (Software as a Medical Device)?

SaMD stands for Software as a Medical Device, defined by the International Medical Device Regulators Forum (IMDRF) as software intended to be used for medical purposes without being part of a hardware medical device. Unlike embedded device software that controls hardware, SaMD operates independently to process data, generate clinical insights, and inform treatment decisions. Examples include AI-powered diagnostic imaging analysis, clinical decision support algorithms, and computational pathology platforms. The FDA has authorized over 950 AI/ML-enabled devices, with the majority being SaMD products.

How does SaMD marketing differ from traditional medical device marketing?

SaMD marketing differs in several fundamental ways. The product is intangible, so you cannot demonstrate it physically at conferences or photograph it for catalogs. Value propositions must lead with clinical outcomes rather than product specifications. Pricing models are typically subscription-based rather than capital purchases. Marketing channels lean heavily on digital rather than field sales. The product evolves continuously through algorithm updates, requiring ongoing communication strategies. Reimbursement is often uncertain, requiring economic justification beyond traditional billing approaches.

What regulatory considerations affect SaMD marketing claims?

SaMD marketing claims must align with the product's specific FDA authorization, whether through 510(k), De Novo, or PMA pathways. Claims about algorithm performance must be supported by analytical validation, clinical validation, and real-world performance data as required by the device's classification level. The FDA's Predetermined Change Control Plan (PCCP) framework allows pre-authorized algorithm modifications, which can be marketed as continuous improvement capability. All promotional materials should go through Medical Legal Regulatory review to ensure compliance.

How should SaMD companies build clinical evidence for marketing?

Build a three-tier evidence strategy. First, analytical validation studies proving the algorithm works correctly on test datasets. Second, clinical validation studies demonstrating clinically meaningful outputs in real clinical scenarios. Third, real-world performance studies showing the product works in actual practice across diverse patient populations and clinical settings. Publish findings in peer-reviewed journals relevant to your target specialty. Hospital evaluation committees, payer medical directors, and specialty societies all rely on published literature when evaluating SaMD products.

What pricing models work best for SaMD products?

Three models dominate. Subscription pricing (monthly or annual per-user fees) lowers adoption barriers and aligns with SaaS conventions but requires ongoing value demonstration to prevent churn. Usage-based pricing (per-study, per-scan) directly aligns cost with value and simplifies ROI calculations. Enterprise licensing (fixed annual fees for unlimited usage) appeals to large health systems that prefer predictable budgeting. The best model depends on your market segment, clinical volume, and competitive landscape. Many successful SaMD companies offer multiple pricing tiers.

How do you address clinician trust concerns with AI-based SaMD?

Address trust through explainability marketing. Show clinicians not just what the algorithm concludes but how it reaches those conclusions. Use heat maps showing which image regions influenced a diagnosis, confidence scores indicating algorithm certainty, and comparison displays showing algorithm output alongside traditional findings. Position the SaMD as a clinical tool that augments rather than replaces clinician judgment. Engage key opinion leaders who can bridge clinical credibility and technical understanding. Publish transparent performance data including sensitivity, specificity, and performance across demographic subgroups.

What are the best marketing channels for SaMD products?

Effective SaMD marketing uses a mix of specialty medical conferences (with live software demonstrations rather than hardware exhibits), healthcare SEO targeting clinical, technical, and economic search queries, peer-reviewed publications providing evidence foundation, KOL engagement with technology-savvy clinical leaders, digital advertising through search and professional networks, and content marketing including white papers, webinars, and case studies. The digital marketing mix should be proportionally larger than for traditional devices, reflecting the software nature of the product.

How is SaMD reimbursement evolving?

SaMD reimbursement is progressing but remains inconsistent. Some products have dedicated CPT codes, such as 92229 for AI-based diabetic retinopathy screening. The AMA has created Category III CPT codes for several AI applications to gather utilization data. CMS has issued National Coverage Determinations for some AI diagnostics. However, many SaMD products must be reimbursed under existing procedure codes as adjuncts. Successful SaMD companies address reimbursement uncertainty by providing coding guidance, developing ROI models demonstrating value beyond reimbursement, and demonstrating that AI increases the volume of independently billable procedures.

Software as a Medical Device (SaMD) Marketing Strategy

What Is SaMD and Why Does It Require a Different Marketing Approach?

Software as a Medical Device, commonly abbreviated as SaMD, refers to software intended to be used for one or more medical purposes that performs these purposes without being part of a hardware medical device. Unlike traditional medical devices where software controls hardware, SaMD operates independently. It processes data, generates clinical insights, and informs treatment decisions through software alone.

The International Medical Device Regulators Forum (IMDRF) formalized this definition, and regulatory agencies worldwide, including the FDA, European Commission (under the MDR and IVDR), and Health Canada, have adopted it. The distinction matters because SaMD products face unique regulatory pathways, reimbursement challenges, and market dynamics that demand specialized marketing strategies.

The SaMD market is expanding rapidly. The FDA has authorized over 950 AI and ML-enabled devices as of early 2025, with the majority being software-only products. Radiology leads with over 75% of authorized AI devices, followed by cardiology, pathology, and ophthalmology. The global SaMD market is projected to exceed $86 billion by 2028, driven by advancements in AI diagnostics, clinical decision support, and computational pathology.

For medical device marketers accustomed to promoting tangible hardware, SaMD presents a paradigm shift. You cannot hand a surgeon your product in a conference exhibit. You cannot photograph it for a product catalog. You cannot demonstrate it at a cadaver lab. SaMD marketing requires different proof points, different channels, different buyer personas, and different value propositions. This guide provides the framework for getting it right.

Our medical device marketing guide provides foundational strategy for all device categories, and the principles here build upon that broader framework with SaMD-specific considerations.

Understanding the SaMD Regulatory Landscape for Marketers

Effective SaMD marketing starts with a thorough understanding of the regulatory landscape, not because marketers need to be regulatory experts, but because the regulatory pathway fundamentally shapes what you can say, when you can say it, and how you prove it.

FDA Classification and Pathways

The FDA classifies SaMD based on the significance of the information provided and the seriousness of the healthcare situation or condition. This creates a risk-based framework with four categories (I through IV in the IMDRF framework) that map to FDA's classification system.

Low risk (Class I): Software that informs clinical management for non-serious conditions. Often exempt from premarket review.
Moderate risk (Class II): Software that drives clinical management for non-serious conditions or informs management for serious conditions. Typically requires 510(k) clearance or De Novo classification.
High risk (Class III): Software that drives clinical management for serious or critical conditions. Requires Premarket Approval (PMA) with clinical evidence.

The FDA's Predetermined Change Control Plan (PCCP) framework, finalized in 2024, is particularly relevant for SaMD marketers. PCCP allows manufacturers to describe anticipated modifications to their AI/ML-based SaMD in advance, enabling the FDA to authorize certain changes without requiring new submissions. This means your product can evolve faster than traditional devices, and your marketing can communicate a roadmap of continuous improvement.

Digital Health Pre-Certification (Pre-Cert) Program

Although the FDA's Digital Health Pre-Certification program has evolved since its initial pilot, the concept of organization-level assessment rather than product-level review continues to influence SaMD regulation. Companies with established quality management systems and track records of safe software development may benefit from streamlined review processes, which is a marketable differentiator.

Clinical Evidence Requirements

SaMD clinical evidence requirements differ from traditional devices. The FDA expects analytical validation (does the algorithm work correctly?), clinical validation (does it produce clinically meaningful outputs?), and in some cases, real-world performance data (does it work in actual clinical practice?). Your marketing evidence strategy must align with these three levels of validation.

SaMD Value Proposition Development

SaMD products deliver value differently than hardware devices, and your value proposition must reflect these differences.

Outcome Improvement vs. Product Features

Traditional device marketing often leads with product specifications: sensor accuracy, battery life, ergonomic design. SaMD marketing must lead with clinical outcomes because the "product" is an algorithm that transforms data into clinical insights. Buyers do not care about the architecture of your neural network. They care about diagnostic accuracy, time savings, and patient outcomes.

For example, an AI-powered radiology SaMD should not lead with "uses a 47-layer convolutional neural network." It should lead with "identifies pulmonary nodules missed by radiologists in 11.3% of CT scans, reducing delayed lung cancer diagnosis." The outcome is the product.

Workflow Integration Value

SaMD that integrates seamlessly into existing clinical workflows creates more value than SaMD that requires workflow disruption. Position your product as a workflow enhancement, not a workflow replacement. Radiologists do not want an AI that replaces them. They want an AI that pre-reads studies, highlights abnormalities, and prioritizes worklists so they can focus on complex cases.

Quantify the workflow value. If your SaMD reduces the time to interpret a study by 22%, calculate what that means in terms of daily throughput, radiologist satisfaction, and patient wait times. These operational metrics resonate with department heads and hospital administrators who make purchasing decisions.

Economic Value

SaMD economics differ from hardware economics. There is no cost of goods sold for manufacturing, no inventory management, no shipping logistics. But there are infrastructure requirements, integration costs, training needs, and ongoing subscription fees. Your value proposition must address total cost of ownership transparently.

Many SaMD products use subscription or per-study pricing models rather than one-time capital purchases. This changes the economic conversation from "can we afford the capital expenditure?" to "does the per-study cost generate positive ROI through improved outcomes, efficiency gains, or revenue capture?"

Free: Medical Device Marketing Guide

Get our comprehensive strategy guide covering surgeon targeting, FDA compliance, SEO, and more.

Download the Guide →

Marketing Channels for SaMD Products

SaMD marketing channels overlap with traditional medtech channels but include digital-native channels that align with the product's software nature.

Medical Conference Strategy

Conferences remain important for SaMD, but the exhibition approach differs. You cannot display hardware on a table. Instead, focus on live demonstrations using real (de-identified) clinical cases, interactive experiences where attendees can test the software, and scientific presentations sharing clinical validation data. The demonstration is the exhibit.

Target specialty-specific conferences where your clinical audience concentrates. RSNA for radiology AI, ACC for cardiology AI, USCAP for pathology AI, and HIMSS for health IT decision-makers. Each conference requires tailored messaging that addresses the specific clinical workflows and pain points of that specialty.

Digital Marketing and SEO

SaMD buyers frequently research products online before engaging vendors. Physicians search for clinical evidence, IT teams evaluate technical specifications, and administrators compare pricing models. A strong healthcare SEO strategy ensures your product appears when these stakeholders search for solutions to their clinical and operational challenges.

Create content optimized for clinical search queries (e.g., "AI-assisted mammography screening accuracy"), technical queries (e.g., "DICOM integration requirements for radiology AI"), and economic queries (e.g., "ROI of AI triage in emergency radiology"). This multi-intent content strategy captures prospects at different stages of the buying journey.

Key Opinion Leader Engagement

KOL engagement for SaMD products requires identifying physicians who are both clinical experts and technology adopters. These individuals bridge the gap between clinical credibility and digital health enthusiasm. Engage them as clinical advisors, beta testers, co-investigators on validation studies, and speakers at educational events.

KOLs in SaMD should be able to speak credibly about both the clinical problem your software addresses and the technical approach it uses. A radiologist who understands deep learning and can explain it to colleagues is far more valuable as an advocate than one who simply endorses the product.

Peer-Reviewed Publication Strategy

For SaMD, peer-reviewed publications are not just nice to have. They are essential marketing assets. Hospital evaluation committees, payer medical directors, and specialty societies all look to the published literature when evaluating SaMD products. A robust publication strategy that includes validation studies, real-world performance data, and health economic analyses provides the evidence foundation for all other marketing activities.

SaMD-Specific Marketing Challenges

Several challenges are unique to SaMD marketing and require deliberate strategies to address.

The Intangibility Problem

You cannot hold SaMD. You cannot photograph it sitting on an OR table. You cannot point to it on a shelf. This intangibility makes it harder to create compelling visual marketing and harder for buyers to perceive value. Address this through screen captures of the software in clinical context, video demonstrations showing the product in workflow, and data visualizations showing clinical impact.

Some SaMD companies have successfully used physical metaphors in their branding: a "second pair of eyes" for AI diagnostic tools, a "clinical copilot" for decision support software. These metaphors make the intangible tangible and help buyers conceptualize the product's role.

Algorithm Transparency and Trust

Clinicians are trained to understand the tools they use. A surgeon understands the mechanical principles of a stapler. A cardiologist understands the physics of ultrasound. But many clinicians do not understand how deep learning algorithms reach their conclusions, creating a trust barrier.

Address this through explainability marketing. Show clinicians not just what your algorithm concludes but how it reaches those conclusions. Heat maps showing which image regions influenced a diagnosis, confidence scores indicating algorithm certainty, and comparison displays showing algorithm output alongside traditional findings all build trust.

Continuous Improvement Messaging

SaMD products can improve continuously through algorithm updates, training on larger datasets, and expanding clinical indications. This is a powerful differentiator, but it creates messaging challenges. How do you market a product that is constantly changing? How do you manage clinical expectations when performance metrics evolve?

Develop a communication strategy for algorithm updates that includes clinical validation of each update, clear documentation of performance changes, and proactive notification to customers. Frame continuous improvement as a benefit: "Unlike hardware devices that are frozen at the time of purchase, our SaMD continuously improves as new evidence becomes available."

Reimbursement Uncertainty

Reimbursement for SaMD products remains inconsistent. Some products have dedicated CPT codes (like the AI-based diabetic retinopathy screening code 92229), while others must be reimbursed under existing procedure codes with AI as an adjunct. This uncertainty makes economic messaging challenging.

Be transparent about the reimbursement landscape. Provide specific coding and billing guidance for each indication. Work with health economics teams to develop ROI models that demonstrate value even in the absence of dedicated reimbursement codes. Some SaMD products have succeeded by demonstrating that they increase the volume of billable procedures rather than requiring their own reimbursement.

SaMD Pricing and Packaging Strategy

SaMD pricing models differ fundamentally from hardware device pricing, and your marketing must reflect the pricing structure you choose.

Subscription vs. Perpetual License

Most SaMD products use subscription-based pricing (monthly or annual per-user or per-study fees) rather than one-time perpetual licenses. Subscription models align cost with usage and lower the barrier to adoption, but they require ongoing value demonstration to prevent churn. Your marketing must justify not just the initial purchase but the ongoing subscription through continuous feature delivery, algorithm improvements, and clinical support.

Usage-Based Pricing

Per-study, per-scan, or per-patient pricing aligns cost with value and appeals to budget-conscious buyers. A radiology AI product priced at $3 per study is easier to evaluate than a $150,000 annual enterprise license. Your marketing should provide clear ROI calculations: if the AI identifies one additional actionable finding per 100 studies, and each finding generates $X in downstream revenue or prevents $Y in liability exposure, the per-study cost is easily justified.

Enterprise Licensing

Large health systems may prefer enterprise agreements with fixed annual fees covering unlimited usage. These agreements simplify budgeting and remove per-study cost concerns. Marketing enterprise deals requires executive-level engagement, system-wide implementation planning, and value propositions that address organizational strategic priorities rather than departmental operational needs.

Building a SaMD Marketing Organization

Marketing SaMD effectively often requires organizational capabilities that traditional medtech marketing teams lack.

Product marketing: SaMD product marketers need to understand software development cycles, agile methodology, and SaaS business metrics in addition to clinical and regulatory knowledge. Hire from the intersection of healthtech and enterprise software rather than from traditional medtech alone.

Clinical marketing: Clinical evidence is the foundation of SaMD marketing. Invest in medical affairs collaboration, clinical publication management, and KOL relationship development. These functions should be closely integrated with marketing rather than siloed in separate departments.

Digital marketing: SaMD marketing leans heavily on digital channels. Invest in SEO, content marketing, marketing automation, and digital advertising capabilities. The digital maturity of your marketing team should match the digital nature of your product.

Customer success: SaMD subscription models require ongoing customer engagement to prevent churn. Customer success functions that monitor usage, drive adoption, and expand accounts are marketing-adjacent activities that directly impact revenue retention.

Our medical device marketing services are designed for the full spectrum of device companies, including SaMD manufacturers who need marketing strategies tailored to the software-as-device model.

Real-World SaMD Marketing Examples

Several SaMD companies have established marketing approaches worth studying.

Viz.ai markets its AI-powered stroke detection platform by emphasizing time savings in stroke triage. Their messaging centers on reducing door-to-treatment time, a metric every stroke center tracks. They publish clinical data showing that Viz.ai reduces time to treatment by an average of 26 minutes, a tangible outcome that resonates with neurologists, emergency physicians, and hospital administrators alike.

Aidoc positions its always-on AI radiology platform as a triage and workflow prioritization tool. Their marketing emphasizes the operational value, helping radiologists identify urgent findings faster, rather than replacing radiologist judgment. This positioning reduces resistance and aligns with how radiologists want to use AI.

IDx (now Digital Diagnostics) took a different approach with its diabetic retinopathy screening AI, marketing it as an autonomous diagnostic that does not require specialist oversight. This positioning targeted primary care settings where access to ophthalmologists is limited, expanding the addressable market beyond traditional specialist channels.

Each of these companies made deliberate positioning choices based on their clinical evidence, regulatory pathway, and target buyer persona. Their marketing success stems from aligning their messaging with how clinicians actually think about the clinical problem their software addresses.

The Future of SaMD Marketing

SaMD marketing will evolve as the category matures. Expect increased emphasis on real-world evidence demonstrating performance across diverse patient populations, greater demand for algorithmic transparency and bias documentation, more sophisticated health economic models justifying AI adoption, and consolidation that creates platform-level SaMD solutions requiring enterprise marketing approaches.

The manufacturers that succeed will be those that market their SaMD products as clinical tools first and technology second, grounding every claim in evidence and every value proposition in measurable clinical or operational outcomes.